trivalent influenza vaccine is one of 92 biologic programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
163 competitors in Acute Lymphoblastic Leukemia
Oncovin
Oncaspar
Wellcovorin
Cerubidine
Fludara
Cellcept
Neupogen
Tepadina
Jakafi
Prograf
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details